Global Antisense Therapy Market Overview:
Global Antisense Therapy Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Antisense Therapy Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Antisense Therapy involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Antisense Therapy Market:
The Antisense Therapy Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Antisense Therapy Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Antisense Therapy Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Antisense Therapy market has been segmented into:
Genetic Disease
Cancer
Infectious Disease
Neurodegenerative Disorders
Cardiometabolic & Renal Disorders
Ocular Disorders
Respiratory Disorders
Skin Disorders
Others
By Application, Antisense Therapy market has been segmented into:
Intravenous Injections
Intrathecal Injections
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Antisense Therapy market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Antisense Therapy market.
Top Key Players Covered in Antisense Therapy market are:
GSK plc
Olix Pharmaceuticals
Inc.
Sanofi
Alnylam Pharmaceuticals
Inc.
Arbutus Biopharma
Benitec Biopharma Inc.
Silence Therapeutics
Ionis Pharmaceuticals
Inc
Bio-Path Holdings Inc.
Antisense Therapeutics Limited.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Antisense Therapy Market Type
4.1 Antisense Therapy Market Snapshot and Growth Engine
4.2 Antisense Therapy Market Overview
4.3 Genetic Disease
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Genetic Disease: Geographic Segmentation Analysis
4.4 Cancer
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Cancer: Geographic Segmentation Analysis
4.5 Infectious Disease
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Infectious Disease: Geographic Segmentation Analysis
4.6 Neurodegenerative Disorders
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Neurodegenerative Disorders: Geographic Segmentation Analysis
4.7 Cardiometabolic & Renal Disorders
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Cardiometabolic & Renal Disorders: Geographic Segmentation Analysis
4.8 Ocular Disorders
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Ocular Disorders: Geographic Segmentation Analysis
4.9 Respiratory Disorders
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.9.3 Respiratory Disorders: Geographic Segmentation Analysis
4.10 Skin Disorders
4.10.1 Introduction and Market Overview
4.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.10.3 Skin Disorders: Geographic Segmentation Analysis
4.11 Others
4.11.1 Introduction and Market Overview
4.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.11.3 Others: Geographic Segmentation Analysis
Chapter 5: Antisense Therapy Market Application
5.1 Antisense Therapy Market Snapshot and Growth Engine
5.2 Antisense Therapy Market Overview
5.3 Intravenous Injections
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Intravenous Injections: Geographic Segmentation Analysis
5.4 Intrathecal Injections
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Intrathecal Injections: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Antisense Therapy Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 GSK PLC
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 OLIX PHARMACEUTICALS
6.4 INC.
6.5 SANOFI
6.6 ALNYLAM PHARMACEUTICALS
6.7 INC.
6.8 ARBUTUS BIOPHARMA
6.9 BENITEC BIOPHARMA INC.
6.10 SILENCE THERAPEUTICS
6.11 IONIS PHARMACEUTICALS
6.12 INC
6.13 BIO-PATH HOLDINGS INC.
6.14 ANTISENSE THERAPEUTICS LIMITED.
Chapter 7: Global Antisense Therapy Market By Region
7.1 Overview
7.2. North America Antisense Therapy Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Genetic Disease
7.2.2.2 Cancer
7.2.2.3 Infectious Disease
7.2.2.4 Neurodegenerative Disorders
7.2.2.5 Cardiometabolic & Renal Disorders
7.2.2.6 Ocular Disorders
7.2.2.7 Respiratory Disorders
7.2.2.8 Skin Disorders
7.2.2.9 Others
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Intravenous Injections
7.2.3.2 Intrathecal Injections
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Antisense Therapy Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Genetic Disease
7.3.2.2 Cancer
7.3.2.3 Infectious Disease
7.3.2.4 Neurodegenerative Disorders
7.3.2.5 Cardiometabolic & Renal Disorders
7.3.2.6 Ocular Disorders
7.3.2.7 Respiratory Disorders
7.3.2.8 Skin Disorders
7.3.2.9 Others
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Intravenous Injections
7.3.3.2 Intrathecal Injections
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Antisense Therapy Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Genetic Disease
7.4.2.2 Cancer
7.4.2.3 Infectious Disease
7.4.2.4 Neurodegenerative Disorders
7.4.2.5 Cardiometabolic & Renal Disorders
7.4.2.6 Ocular Disorders
7.4.2.7 Respiratory Disorders
7.4.2.8 Skin Disorders
7.4.2.9 Others
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Intravenous Injections
7.4.3.2 Intrathecal Injections
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Antisense Therapy Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Genetic Disease
7.5.2.2 Cancer
7.5.2.3 Infectious Disease
7.5.2.4 Neurodegenerative Disorders
7.5.2.5 Cardiometabolic & Renal Disorders
7.5.2.6 Ocular Disorders
7.5.2.7 Respiratory Disorders
7.5.2.8 Skin Disorders
7.5.2.9 Others
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Intravenous Injections
7.5.3.2 Intrathecal Injections
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Antisense Therapy Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Genetic Disease
7.6.2.2 Cancer
7.6.2.3 Infectious Disease
7.6.2.4 Neurodegenerative Disorders
7.6.2.5 Cardiometabolic & Renal Disorders
7.6.2.6 Ocular Disorders
7.6.2.7 Respiratory Disorders
7.6.2.8 Skin Disorders
7.6.2.9 Others
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Intravenous Injections
7.6.3.2 Intrathecal Injections
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Antisense Therapy Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Genetic Disease
7.7.2.2 Cancer
7.7.2.3 Infectious Disease
7.7.2.4 Neurodegenerative Disorders
7.7.2.5 Cardiometabolic & Renal Disorders
7.7.2.6 Ocular Disorders
7.7.2.7 Respiratory Disorders
7.7.2.8 Skin Disorders
7.7.2.9 Others
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Intravenous Injections
7.7.3.2 Intrathecal Injections
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Antisense Therapy Scope:
|
Report Data
|
Antisense Therapy Market
|
|
Antisense Therapy Market Size in 2025
|
USD XX million
|
|
Antisense Therapy CAGR 2025 - 2032
|
XX%
|
|
Antisense Therapy Base Year
|
2024
|
|
Antisense Therapy Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
GSK plc, Olix Pharmaceuticals, Inc., Sanofi, Alnylam Pharmaceuticals, Inc., Arbutus Biopharma, Benitec Biopharma Inc., Silence Therapeutics, Ionis Pharmaceuticals, Inc, Bio-Path Holdings Inc., Antisense Therapeutics Limited..
|
|
Key Segments
|
By Type
Genetic Disease
Cancer
Infectious Disease
Neurodegenerative Disorders
Cardiometabolic & Renal Disorders
Ocular Disorders
Respiratory Disorders
Skin Disorders
Others
By Applications
Intravenous Injections
Intrathecal Injections
|
